CN203144400U - Kit for acute leukemia susceptibility detection - Google Patents
Kit for acute leukemia susceptibility detection Download PDFInfo
- Publication number
- CN203144400U CN203144400U CN 201320159603 CN201320159603U CN203144400U CN 203144400 U CN203144400 U CN 203144400U CN 201320159603 CN201320159603 CN 201320159603 CN 201320159603 U CN201320159603 U CN 201320159603U CN 203144400 U CN203144400 U CN 203144400U
- Authority
- CN
- China
- Prior art keywords
- film
- medicine
- prepackage
- holes
- culture plate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The utility model provides a kit for acute leukemia susceptibility detection. The kit comprises a kit body, a susceptibility detection component, a designation card and a specification, wherein the susceptibility detection component, the designation card and the specification are placed inside the kit body. The kit is characterized in that the susceptibility detection component comprises an acute leukemia medicine medical membrane, a blank medical membrane and a cell culture plate, wherein the acute leukemia medicine medical membrane, the blank medical membrane and the cell culture plate are prepackaged according to a set chemotherapy regimen to form a prepackaged culture plate, or the acute leukemia medicine medical membrane and the blank medical membrane in individual packages together with the cell culture plate form an adjustable suit culture plate. When the kit provided by the utility model is applied to the acute leukemia anti-tumor susceptibility detection, not only the operation efficiency of the tumor susceptibility detection is improved to facilitate the operation, but also the accuracy of the susceptibility detection is greatly improved, detection medicine use amount is greatly reduced, medicine use cost is saved, the economical efficiency of the susceptibility detection is improved, and especially, the kit is also suitable for the susceptibility detection of combined chemotherapy.
Description
Technical field
The utility model relates to a kind of device for antitumor susceptibility test, specifically, relates to a kind of test kit for the detection of acute leukemia susceptibility.
Background technology
Malignant tumour is serious harm human life and healthy common disease and frequently-occurring disease, is to cause one of disabled and early dead principal disease, and in 35～59 years old age group, malignant tumour occupies first of the cause of the death.Data shows that sending out case load China's malignant tumour year is 2,000,000, and is dead about 1,500,000, and with 3% speed increase and be rejuvenation trend, occupy mortality ratio in all kinds of diseases.
The world comprises operation, radiotherapy, chemotherapy, endocrine therapy and biological immune treatment etc. to the main treatment means of malignant tumour at present.In many means for the treatment of malignant tumor, chemotherapy is as a kind of methods for the treatment of of general, might farthest kill tumour cell in patient's body than additive method, and therefore, chemotherapy is occupied important status in treating malignant tumor.Along with the development of medical science, chemotherapy no longer has been the means that play the palliative therapy effect merely, from appeasing to the radical cure transition.
1998, the World Health Organization proposes, use suitably, chemotherapy has become the radical treatment means that can cure tumour in part tumour (malignant trophoblastic tumor, acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, carcinoma of testis, acute myeloblastic leukemia, embryonal rhabdomyosarcoma, tinea 4, the anti-acute leukemia of minicell and ovarian cancer etc.).After adjuvant chemotherapy, can mammary cancer, osteogenic sarcoma, large bowel cancer, osteosarcoma, retinoblastoma, soft tissue sarcoma and the nephroblastoma etc. be arranged curable tumour.
Although chemotherapy is occupied important status in the treatment of malignant tumour, in clinical practice, the result is often not fully up to expectations.Wherein, it is the common factor that causes the chemotherapy of tumors failure that tumour cell produces resistance to chemotherapeutics, also is the key difficult problem of puzzlement oncotherapy.The resistance problem is very general clinical problem, estimates according to American Cancer Society, and the patient because of tumor mortality more than 90% is being subjected to the resistance influence in varying degrees.
Drug resistance of tumor cell is divided into primary and acquired resistance two big classes.Common way is clinically at present, follow the card result of study according to the test of international clinical tumor, learn that different chemotherapeutics is to different tumor treatment susceptibility differences, be that each tumour has corresponding effective chemotherapy medicament sensitive spectrum, thereby the scheme for combining of selecting the single medicine of the highest chemotherapy of curative effect or multiple medicine to form is treated.But often run into such situation clinically, be known as the effective treatment plan of certain tumour through following card research, and the patient who has is had no effect.Be a kind of medicine with milestone significance as Zorubicin to infiltrative breast carcinoma, but still have 50% infiltrative breast carcinoma patient insensitive to this medicine.And for example be good for and select, the curative effect that the anti-acute leukemia of non-small cell is generally acknowledged is obvious, but also has the patient's curative effect more than 60% also not obvious.
Tumour exists tangible individual difference to various chemotherapeutics.Be different tumor types or the different patients of same type, even same patient is in the different morbidity stages, to the susceptibility of chemotherapy and incomplete same, the result for the treatment of difference is also very big.So far the combined utilization that does not also have a kind of chemotherapeutics or several chemotherapeutics can be effective to a certain tumour 100%.Clinically, use with a kind of chemotherapeutics or with the different tumour patient of a kind of chemotherapy regimen treatment, obviously have certain blindness.Therefore, carrying out the tumour drug sensitive test at different patients before chemotherapy selects effective chemotherapeutics to carry out chemotherapy to seem very necessary.For this reason, set up a kind ofly as the bacterium sensitization test, by sensitivity testing method relatively reliably, different patients is accurately screened responsive chemotherapeutics, and determine its dosage, really realize clinical personalized medicine.
Tumour drug sensitive test is at present operated required medicine to face with now joining, and the tumour drug sensitive test need be tested multiple antitumor drug, and the soup prepared and diluted is loaded down with trivial details, and the required antitumor drug dosage of tumour drug sensitive test is little, sampling inconvenience.The part drug solution following shelf time of state is short, and remainder can only be scrapped, and causes the waste of medicine, especially expensive medicine.
CN93111551.5 discloses tumour chemotherapy medicament sensitive pretest agent compounding method and test kit, and this patent is pre-installed on 8 kinds of antitumor drugs commonly used in the specimen bottle by setting dosage.But this method is not easy to the test of Combination chemotherapy, and is not easy to the dose titration of scheme.
CN03102260.X adopts the method for prefabricated medicine sensitive detecting plate, and antitumor drug is added in the check-out console by calculating dosage, and freeze-drying, packing are used for the tumour drug sensitive test.This method is not easy to the test of Combination chemotherapy equally, and is not easy to the dose titration of scheme.
Clinical have the method for the interim preparation of a small amount of employing antitumor drug to carry out the antitumor drug antibiotics susceptibility test at present, and still, there are many problems in this method: accurate concentration the unknown of compounding pharmaceutical, and the accuracy of institute's preparating liquid leaves a question open; The antitumor drug antibiotics susceptibility test of clinical oral administration antitumor drug can't carry out; The individual operations error is big.
Operation and saving cost for the ease of the tumour drug sensitive test, we with the tumour medicine of various anti-acute leukemias commonly used be prepared into dosage accurately, good stability, can be in tumor cell culture liquid rapidly-soluble aseptic medicine film, and the medicine film cut into slices packing accurately by using dosage.
The utility model content
The utility model provides a kind of test kit for the detection of acute leukemia medicine susceptibility, and its technical scheme is as follows:
The utility model provides a kind of test kit for the detection of acute leukemia susceptibility, formed by box body, susceptibility detection components, designation card and specification sheets, susceptibility detection components, designation card and specification sheets place in the box, it is characterized in that described susceptibility detection components comprises anti-acute leukemia medicine medicine film, blank medicine film and Tissue Culture Plate.
Test kit described above is characterized in that described susceptibility detection components also comprises medicine activating enzymes packing.
Test kit described above is characterized in that in the described susceptibility detection components, and anti-acute leukemia medicine medicine film and blank medicine film and Tissue Culture Plate form the prepackage culture plate by setting the chemotherapy regimen prepackage.
Test kit described above is characterized in that in the described susceptibility detection components that anti-acute leukemia medicine medicine film and blank medicine film have been formed adjustable suit culture plate with independent packaging and Tissue Culture Plate respectively.
Test kit described above, it is characterized in that described anti-acute leukemia medicine medicine film is selected from homoharringtonine film, methotrexate film, cytosine arabinoside film, vindesine film, vincristine(VCR) film, daunorubicin film, epirubicin film, a kind of or two or more in aclarubicin film, Zorubicin film, mitoxantrone film, pirarubicin film, Etoposide film, teniposide film, Carubicin film, endoxan film, fludarabine film, the dexamethasone film.
Test kit described above is characterized in that described Tissue Culture Plate is 24 porocyte culture plates.
Test kit described above is characterized in that described medicine activating enzymes are hepatomicrosome.
As preferably, test kit described above is characterized in that described prepackage culture plate is the acute lymphoblastic leukemia medicine sensitive detecting plate, and it is prepackage 24 well culture plates, and the pre-powder charge film in hole is as follows:
2 Kong Zhongwu medicine films
The blank medicine film of prepackage in 2 holes
Prepackage epirubicin film in 2 holes
Prepackage darubicin film in 2 holes
Prepackage fludarabine film in 2 holes
Prepackage Zorubicin film in 2 holes
Prepackage methotrexate film in 2 holes
Prepackage daunorubicin film, vincristine(VCR) film and endoxan film in 2 holes
Prepackage mitoxantrone film and cytosine arabinoside film in 2 holes
Prepackage daunorubicin film, vincristine(VCR) film and dexamethasone film in 2 holes
Prepackage teniposide film and cytosine arabinoside film in 2 holes
Prepackage cytosine arabinoside film, vincristine(VCR) film, endoxan film, teniposide film and dexamethasone film in 2 holes.
As preferably, test kit described above is characterized in that described prepackage culture plate is the acute nonlymphocytic leukemia medicine sensitive detecting plate, and it is prepackage 24 well culture plates, and the pre-powder charge film in hole is as follows:
2 Kong Zhongwu medicine films
The blank medicine film of prepackage in 2 holes
Prepackage pirarubicin film in 2 holes
Prepackage Zorubicin film in 2 holes
Prepackage cytosine arabinoside film in 2 holes
Prepackage darubicin film in 2 holes
Prepackage cytosine arabinoside film and daunorubicin film in 2 holes
Prepackage cytosine arabinoside film and mitoxantrone film in 2 holes
Prepackage cytosine arabinoside film and darubicin film in 2 holes
Prepackage cytosine arabinoside film and Zorubicin film in 2 holes
Prepackage cytosine arabinoside film and homoharringtonine film in 2 holes
Prepackage cytosine arabinoside film, homoharringtonine film and daunorubicin film in 2 holes.
In the utility model test kit, the susceptibility detection components be for resisting acute leukemia medicine medicine film and 24 porocyte culture plates by the prepackage culture plate of setting the chemotherapy regimen prepackage, also can be two kinds of the adjustable suits that make up of medicine film packing and blank 24 porocyte culture plates independently.
Contain an acute leukemia antitumor drug medicine film packing box, a Tissue Culture Plate commonly used in each adjustable suit.The code name of each medicine film is arranged on the medicine film packing, and each Tissue Culture Plate attaches a designation card, is used for the pharmaceutical cpd in each hole of mark.
Various antitumour drug films and blank medicine film place independently aseptic the lid in the small plastic box respectively, in the big plastics casing of again small plastic box being packed in order.Various medicine activating enzymes place independently aseptic the lid in the small plastic box respectively, in the big plastics casing of again small plastic box being packed in order.
In the medicine film packing free baiyao film and anti-acute leukemia medicine medicine film are arranged, anti-acute leukemia medicine medicine film includes but not limited to homoharringtonine film, methotrexate film, cytosine arabinoside film, vindesine film, vincristine(VCR) film, daunorubicin film, epirubicin film, aclarubicin film, Zorubicin film, mitoxantrone film, pirarubicin film, Etoposide film, teniposide film, Carubicin film, endoxan film, fludarabine film, dexamethasone film.
Tissue Culture Plate is 24 porocyte culture plates, and designation card is 24 lattice, is used for the pharmaceutical cpd in each hole of mark.
During use, blank, the contrast of blank medicine film and various chemotherapy regimen are marked on respectively on the designation card, press the designation card content and add the medicine film in Tissue Culture Plate, add the tumour cell suspension, vibration makes medicine film dissolving mixing.For no external activity, need the endoxan of enzymes metabolism activation, need in culture plate, add the activating enzymes hepatomicrosome.
The prepackage culture plate comprises acute lymphoblastic leukemia check-out console and acute nonlymphocytic leukemia check-out console, 10 chemotherapy regimens of each 24 well culture plates configuration, 1 blank medicine film scheme, 1 blank scheme, 2 multiple holes of each scheme.
The chemotherapy regimen that the prepackage culture plate sets is worked out with reference to the standard chemotherapy regimen of up-to-date practice guidelines.By the setting scheme medicine film is packed in each hole of culture plate.
Medicine medicine film described in the utility model, normally, medicine medicine film contains 0.0001%～30% antitumor drug, 50%～98% film forming material and 1%～20% softening agent by weight percentage.Wherein, described film forming material includes but not limited to polyvinyl alcohol, hypromellose, hydroxypropylcellulose, Xylo-Mucine, polyvinylpyrrolidone, polyethylene amine, polyethylene amido-acetal derivative, polyvinyl pyridine derivative, gelatin, gum arabic, shellac, agar, Lalgine and salt thereof, zein, starch, dextrin, bletilla striata glue etc.Preferred polyvinyl alcohol 04-88 and the polyvinyl alcohol 05-88 of using.Described softening agent is selected from glycerine, polyoxyethylene glycol, ethylene glycol, propylene glycol, sorbyl alcohol, triethyl citrate etc.
Medicine medicine film described in the utility model can prepare with ordinary method in this area, for example can make anti-acute leukemia medicine medicine film as follows:
(1) film forming material is added to the water stirring and dissolving or heating for dissolving;
(2) add softening agent and antitumor drug, stirring and dissolving is even, adopts heating, leaves standstill or mode such as ultrasonic outgases;
(3) with above-mentioned solution coat in membrane equipment, adopt mode dryings such as hot blast or cold wind;
(4) demoulding is measured content, and carries out divided dose according to measurement result and cut apart;
(5) the medicine film after will cutting apart adopts radiation exposure sterilization or ethylene oxide sterilizing, preferred radiation exposure sterilization.
The plasma peak concentration preparation of various tumor chemotherapeutic drug medicine film reference drugs in human body according to medicine film assay result, is cut into the chemotherapeutics that contains the 1ml plasma peak concentration with every medicine film, blank medicine film cutting area 1cm
2
For the ease of the operation of tumour antibiotics susceptibility test, the medicine film needs and can be dissolved in fast in the tumor cell culture liquid.Therefore film forming material will be easy to dissolving, and the thickness of film and area will be controlled in suitable scope, guarantees dissolution rate and physical strength.Preferred 0.04mm～the 0.15mm of thickness.Shape can be circle, square or rectangular, and area is preferably 0.5cm
2～16cm
2, to adapt to the Tissue Culture Plate of corresponding specification.1cm of the present invention
2The film of size can dissolving in 100 seconds in the 1ml nutrient solution.
Described blank medicine film refers to not contain the medicine film of antitumor drug, can be prepared according to above-mentioned anti-acute leukemia medicine medicine membrane method, but not add anti-acute leukemia medicine.
The utility model is in carrying out anti-acute leukemia antibiotics susceptibility test, not only improve the operation efficiency of tumour antibiotics susceptibility test, make easy and simple to handle, and improved the accuracy of antibiotics susceptibility test greatly, significantly reduce the testing drug consumption, save drug cost, improve the economy of antibiotics susceptibility test, particularly, also be applicable to the antibiotics susceptibility test of combined chemotherapy.
Description of drawings
The acute nonlymphocytic leukemia susceptibility detects prepackage 24 well culture plate vertical views in Fig. 1: embodiment 1 utility model;
The acute nonlymphocytic leukemia susceptibility detects prepackage 24 well culture plate plan views in Fig. 2: embodiment 1 utility model;
Designation card in Fig. 3: embodiment 1 utility model.
Wherein:
Among Fig. 1,2, A-D is the hole row number of culture plate, and 1-6 is the hole row number of culture plate, and the combination of the row of hole correspondence number and row number is the numbering in hole, and for example: A6 represents in the hole hole of capable the 6th row of the A of culture plate.
Among Fig. 3, every lattice numbering in the designation card is corresponding to the hole numbering of culture plate.
In 24 well culture plates, the pre-powder charge film in hole is as follows:
No medicine film in the A1-A2 hole
The blank medicine film of prepackage in the A3-A4 hole
Prepackage pirarubicin film in the A5-A6 hole
Prepackage Zorubicin film in the B1-B2 hole
Prepackage cytosine arabinoside film in the B3-B4 hole
Prepackage darubicin film in the B5-B6 hole
Prepackage cytosine arabinoside film and daunorubicin film in the C1-C2 hole
Prepackage cytosine arabinoside film and mitoxantrone film in the C3-C4 hole
Prepackage cytosine arabinoside film and darubicin film in the C5-C6 hole
Prepackage cytosine arabinoside film and Zorubicin film in the D1-D2 hole
Prepackage cytosine arabinoside film and homoharringtonine film in the D3-D4 hole
Prepackage cytosine arabinoside film, homoharringtonine film and daunorubicin film in the D5-D6 hole.
Embodiment
Embodiment 1: the susceptibility detection kit that is used for the acute nonlymphocytic leukemia screening anti-tumor medicine
The utility model test kit detects prepackage 24 well culture plates (Fig. 1,2), designation card (Fig. 3) and specification sheets by box body, acute nonlymphocytic leukemia susceptibility and forms.The acute nonlymphocytic leukemia susceptibility detects prepackage 24 well culture plates, designation card and specification sheets and places box.Specification sheets is explanation and introduces test kit, is convenient to the user and correctly uses this test kit.
Before chemotherapy, extract 1 routine acute lymphoblastic leukemia peripheral blood of patients 10ml (anticoagulant heparin) under the Aseptic technique, in the decontamination chamber, isolate the leukemia cell through FIcoll liquid, through the nutrient solution washing, place the RPMI1640 culture system to make 1 * 10
6The cell suspension of/ml.
The cell suspension kind is in prepackage 24 well culture plates (Fig. 1 or 2) (1ml/ hole), and vibration makes medicine film dissolving mixing, and in designation card (Fig. 3) record.37 ℃, 5% carbonic acid gas saturated humidity were cultivated 24 hours.Centrifugal collection suspension cell, Eppendorf centrifuge rotating speed 2000RPM, centrifugation time 5min abandons substratum.With twice of cold PBS washed cell (2000RPM, centrifugation time 5min collecting cell).With 400 μ l 1X Binding Buffer suspension cells, concentration is approximately 1 * 10
6/ ml.In cell suspending liquid, add 5 μ l Annexin V-FITC, under 2-8 ℃ of lucifuge condition, hatched 15 minutes behind the mixing gently.Adding behind the 10 μ l PI gently mixing hatched 5 minutes under 2-8 ℃ of lucifuge condition.In 1 hour, detect control group and medicine group apoptosis and downright bad quantity with flow cytometer, calculate the inhibiting rate of medicine, the susceptibility of assessment medicine.The results are shown in Table 1.
The susceptibility of table 1 antibiotics susceptibility test
| Medicine | Susceptibility (%) |
| The pirarubicin film | 40 |
| The Zorubicin film | 30 |
| The cytosine arabinoside film | 20 |
| The darubicin film | 15 |
| Cytosine arabinoside film+daunorubicin film | 50 |
| Cytosine arabinoside film+mitoxantrone film | 45 |
| Cytosine arabinoside film+darubicin film | 55 |
| Cytosine arabinoside film+Zorubicin film | 35 |
| Cytosine arabinoside film+homoharringtonine film | 60 |
| Cytosine arabinoside film+homoharringtonine film+daunorubicin film | 50 |
(inhibiting rate=((blank medicine film control group viable cell-experimental group viable cell)/blank medicine film control group viable cell) * 100%; Inhibiting rate＞50% is responsive).
Claims (8)
1. one kind is used for the test kit that the acute leukemia susceptibility detects, formed by box body, susceptibility detection components, designation card and specification sheets, susceptibility detection components, designation card and specification sheets place in the box, it is characterized in that described susceptibility detection components comprises anti-acute leukemia medicine medicine film, blank medicine film and Tissue Culture Plate.
2. test kit according to claim 1, if desired, described susceptibility detection components also can comprise medicine activating enzymes packing.
3. test kit according to claim 1 is characterized in that in the described susceptibility detection components, and anti-acute leukemia medicine medicine film and blank medicine film and Tissue Culture Plate form the prepackage culture plate by setting the chemotherapy regimen prepackage.
4. test kit according to claim 1 is characterized in that in the described susceptibility detection components, and anti-acute leukemia medicine medicine film and blank medicine film have been formed adjustable suit culture plate with independent packaging and Tissue Culture Plate respectively.
5. according to each described test kit of claim 1-4, it is characterized in that described anti-acute leukemia medicine medicine film is selected from homoharringtonine film, methotrexate film, cytosine arabinoside film, vindesine film, vincristine(VCR) film, daunorubicin film, epirubicin film, a kind of or two or more in aclarubicin film, Zorubicin film, mitoxantrone film, pirarubicin film, Etoposide film, teniposide film, Carubicin film, endoxan film, fludarabine film, the dexamethasone film.
6. according to each described test kit of claim 1-4, it is characterized in that described Tissue Culture Plate is 24 porocyte culture plates.
7. test kit according to claim 2 is characterized in that described medicine activating enzymes are hepatomicrosome.
8. test kit according to claim 3 is characterized in that described prepackage culture plate is the acute lymphoblastic leukemia medicine sensitive detecting plate, and it is prepackage 24 well culture plates, and the pre-powder charge film in hole is as follows:
2 Kong Zhongwu medicine films
The blank medicine film of prepackage in 2 holes
Prepackage epirubicin film in 2 holes
Prepackage darubicin film in 2 holes
Prepackage fludarabine film in 2 holes
Prepackage Zorubicin film in 2 holes
Prepackage methotrexate film in 2 holes
Prepackage daunorubicin film, vincristine(VCR) film and endoxan film in 2 holes
Prepackage mitoxantrone film and cytosine arabinoside film in 2 holes
Prepackage daunorubicin film, vincristine(VCR) film and dexamethasone film in 2 holes
Prepackage teniposide film and cytosine arabinoside film in 2 holes
Prepackage cytosine arabinoside film, vincristine(VCR) film, endoxan film, teniposide film and dexamethasone film in 2 holes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201320159603 CN203144400U (en) | 2013-03-26 | 2013-03-26 | Kit for acute leukemia susceptibility detection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201320159603 CN203144400U (en) | 2013-03-26 | 2013-03-26 | Kit for acute leukemia susceptibility detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203144400U true CN203144400U (en) | 2013-08-21 |
Family
ID=48971943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201320159603 Expired - Fee Related CN203144400U (en) | 2013-03-26 | 2013-03-26 | Kit for acute leukemia susceptibility detection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203144400U (en) |
-
2013
- 2013-03-26 CN CN 201320159603 patent/CN203144400U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Terenzi et al. | Anticancer metal drugs and immunogenic cell death | |
| Ling et al. | Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway | |
| Trejo-Solís et al. | Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma | |
| Gao et al. | Effects of Ganopoly®(A ganoderma lucidum polysaccharide extract) on the immune functions in Advanced‐Stage cancer patients | |
| Chen et al. | The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex | |
| Al-Hussaini et al. | Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma | |
| Elhag et al. | The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines | |
| Imtiaz et al. | VITAMIN-D status at breast cancer diagnosis: correlation with social and environmental factors and DIETRY INTAKE | |
| Hassan et al. | Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells | |
| CN110433290A (en) | Cryptotanshinone and the combination of TKI inhibitor are preparing the application in Ph+ acute lymphoblastic leukemia chemotherapeutics | |
| CN203144400U (en) | Kit for acute leukemia susceptibility detection | |
| CN203144402U (en) | Kit for antineoplastic drug sensitivity test | |
| CN203144399U (en) | Kit for colorectal cancer susceptibility detection | |
| CN203144410U (en) | Kit for breast cancer drug sensitivity test | |
| CN203144408U (en) | Kit for gastric cancer drug sensitivity test | |
| CN203144405U (en) | Kit for lung cancer susceptibility detection | |
| Juan et al. | Probiotics for the treatment of docetaxel-related weight gain of breast cancer patients—a single-center, randomized, double-blind, and placebo-controlled trial | |
| Liu et al. | Ganoderma lucidum fruiting body extracts inhibit colorectal cancer by inducing apoptosis, autophagy, and G0/G1 phase cell cycle arrest in vitro and in vivo | |
| CN203144409U (en) | Kit for esophagus cancer drug sensitivity test | |
| CN203144403U (en) | Kit for detecting drug sensitivity of pancreatic cancer | |
| CN203144404U (en) | Kit for cervical cancer susceptibility detection | |
| CN103088102B (en) | Sterile instant type medicine film and tumor drug sensitivity testing application thereof | |
| CN203144401U (en) | Kit for ovarian cancer drug sensitivity test | |
| KR102024322B1 (en) | A composition for enhancing radiation sensitivity and an anticancer adjuvent composition comprising ginsenoside rg3 | |
| Zhang et al. | Effects of acupuncturing Pishu combined with Ginsenoside Rg3 on the immune function of rats with chronic fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161021 Address after: 215007 No. 85 East Main Street, Jiangsu, Suzhou Patentee after: Suzhou innovac Medical Technology Consulting Co. Ltd. Address before: Xinghu street Suzhou Industrial Park in Jiangsu province 215125 No. 218 BioBAY A2 building room 330A Patentee before: Suzhou MacWell Biological Medicine Science and Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130821 Termination date: 20180326 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |